SMARCA4 and neoplasm: From these pathological observations, it is suggested that an undifferentiated tumor component with a SMARCA4 deficiency arose, in part, from a background of preexisting urothelial carcinoma, resulting in early retroperitoneal recurrence after TUR‐BT.